▶주메뉴 바로가기
▶본문 바로가기
South Korean biotech firm Bridge Biotherapeutics CEO Lee Jung-kyu announced Nov. 22 that the company plans to expand further after going public in December. The company expects to be listed on the s...
SK Biopharmaceuticals said Nov. 22 its anti-epileptic drug has won approval from the US Food and Drug Administration. The company said the FDA granted approval of XCOPRI, or cenobamate tablets, f...
South Korea’s Samsung Bioepis said Nov. 20 that the US Food and Drug Administration has started reviewing its application for sales of SB8, a proposed biosimilar referencing Avastin. Samsung Group’s...
SK Biopharm announced on Nov. 18 that its narcolepsy drug Sunosi received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Narcolepsy is...
Celltrion Pharm, the generic arm of Celltrion, announced Nov. 14 that its sales jumped 36.6 percent in the third quarter from a year earlier to 47.43 billion won ($40.7 million). The South Korean co...
Samsung Biologics announced Nov. 14 that it has received 27001 security certification from the Geneva-based International Organization for Standardization. The company emphasized that it is the firs...
Korean biotech firm Hugel announced Nov. 12 that its operating profit jumped 225 percent in the third quarter from a year earlier to 18.2 billion won ($15.57 million). Its sales increased by 46.4 pe...
GOTTINGEN, Germany -- Behind the market expansion of Samsung’s biologics business is 149-year-old Sartorius, a German firm that has helped it grow rapidly. Founded in 1870, the German company suppli...
South Korean pharmaceutical firm Samsung Bioepis said Nov. 7 it has entered into a new commercialization agreement worth $370 million with US partner Biogen. Under the partnership, Biogen will be...
Celltrion announced on Nov. 5 that it will start phase 3 clinical trials of its patch-type donepezil, a medication that aims to treat people with Alzheimer’s disease, jointly with local drugmaker Icu...
Bio company SillaJen announced Oct. 31 it will pay back 110 billion won (94.25 million), which it received by issuing convertible bonds, to Kiwoon Securities in March. “The annual interest rate for ...
South Korea’s Health Ministry said Oct. 30 that it is considering revoking Kolon Life Science’s innovative drug company certification for mislabeling and falsely reporting ingredients in its gene the...
Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30. Sales o...
The 30th CPhI Worldwide 2019, the biggest global event of the year for the pharmaceutical industry, is set to take place at Messe Frankfurt in Germany from Nov. 5 to 7. Every year, CPhI brings toget...
South Korean biotech firm Bridge Biotherapeutics announced Oct. 25 that it had received preliminary screening approval for Kosdaq listing. The company applied for approval Sept. 3 and expects to be ...
Chaebol families borrow almost W5tr against stocks
Seoul to back local chipmakers after US info request
Hana partners with Hyundai, Kia for connected car financial services
Kakao Bank, Dell heads discuss future finance platform
Tightened credit lending continues amid eased rules on housing loans
Homegrown private equity firm STIC Investments to go public in December
Boxed-in Kospi leads to surge in forced liquidations
[Law Talk] Trademark issues in the world of the metaverse
October 20, 2021
![[Law Talk] Trademark issues in the world of the metaverse](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2021/10/18/20211018000246_0.jpg&md=20211018102223)
